Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Table 1 Basic characteristics of study population for the value of serum pyruvate kinase Isoenzyme M2 and carcinoembryonic antigen in colorectal cancer mass screening in Hangzhou, China, 2006-2008 (mean ± SD)

Colorectal lesion	n	Gender		Age (yr)	M2-PK (U/mL)	CEA (ng/mL)
		Male	Female
Colorectal cancer
Stage I and II	55	53	40	59.17 ± 10.71	13.10 ± 12.07	5.74 ± 7.49
Stage III	38				14.75 ± 13.39	5.68 ± 5.43
Advanced adenoma	41	25	16	60.17 ± 7.78	8.58 ± 7.65	2.68 ± 1.43
Adenoma	137	68	69	60.34 ± 8.16	6.70 ± 6.97	2.58 ± 3.74
Nonadenomatous polyp	47	25	22	59.04 ± 8.08	5.13 ± 3.73	2.55 ± 2.09
IBD	7	1	6	57.43 ± 7.16	2.51 ± 1.94	1.71 ± 0.91
Normal	158	56	102	57.15 ± 7.96	2.96 ± 2.17	1.98 ± 1.02

IBD: Inflammatory bowel disease; M2-PK: M2-pyruvate kinase; CEA: Carcinoembryonic antigen.